Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
CD19 Molecule (CD19) antibody (FITC)
|Synonyms||B4, MGC12802, AW495831, SPNS1, MGC109570, CD19|
Alternatives Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro))
|2 references available|
|Quantity||100 tests/ml (Variants)|
|Price||726.00 $ Plus shipping costs $45.00|
|Description||B-lymphocyte antigen CD19 also known as CD19 (Cluster of Differentiation 19), is a protein that in humans is encoded by the CD19 gene. This gene encodes a cell surface molecule that assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. CD19 is expressed on follicular dendritic cells and B cells. It is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. The function of the CD19 molecule is related to signal transfer and is involved in regulation of B cell proliferation. CD19 is considered to be a characteristic B cell marker and therefore commonly used in routine immunophenotyping. CD19 may also be expressed on follicular dendritic cells. CD19 (HD37) is present on all peripheral blood B cells. CD19 is also expressed on precursor B cells during maturation, but not on mature plasma cells.|
|Specificity||CD19 recognizes a 95 kD transmembrane glycoprotein.|
HD37 is a mouse monoclonal IgG1 antibody raised against CD19.
|Application Notes||CD19 (HD37) can be applied in flow cytometry and in immunohistochemistry using frozen tissue sections. Optimal antibody dilution should be determined by titration. Progenitor B cells mature in bone marrow and subsequently appear as mature CD19+ B cells in blood. After contact with foreign antigens and the appropriate T cell help, they may further differentiate to specific antibody-producing plasma cells. Detection of CD19 expressing cells is important in the diagnosis of leukemic precursor B cells (pre-B ALL), mature B cells (B ALL), and plasma cells. Distinction between subtypes of these (acute) leukemias can be performed using CD19 antibodies together with monoclonal antibodies to cytoplasmic or membrane Ig. A large number of B cell disorders can be effectively characterized by expression of CD19 and one or more additional antigens. One example is hairy cell leukemia (HCL), which shows specific expression of CD11c, CD19, CD20 and CD103. The combination CD103/CD19 is an important tool for diagnosis of HCL. Other valuable antibody combinations for distinction between different leukemias using CD19 antibodies are CD5/CD19 (e.g. Chronic Lymphatic Leukemia), CD10/CD19 (common ALL and pre-B ALL) and CD19/cyCD79a (Acute B cell leukemia).|
|Buffer||0.01 M sodium phosphate, 0.15 M NaCl, 0.2% BSA, 0.09% sodium azide, pH 7.3.|
|Storage||Store at 4°C.|
|Research Area||Stem Cells, Hematopoietic Progenitors, Hematopoietic Stem Cells, Adaptive Immunity, CD Antigens, Surface Receptors of Immune Cells|
|Restrictions||For Research Use only|
Loken, Shah, Dattilio et al.: "Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development." in: Blood, Vol. 70, Issue 5, pp. 1316-24, 1987 (PubMed).
Meeker, Miller, Link et al.: "A unique human B lymphocyte antigen defined by a monoclonal antibody." in: Hybridoma, Vol. 3, Issue 4, pp. 305-20, 1985 (PubMed).